Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 7Breast 1

Conditions

Breast Neoplasms 628Neoplasm Metastasis 38HER2-positive Breast Cancer 33Breast Neoplasms, Male 30Inflammatory Breast Neoplasms 20Brain Neoplasms 18Stomach Neoplasms 16Neoplasms 16Carcinoma, Non-Small-Cell Lung 14Triple Negative Breast Neoplasms 12Colorectal Neoplasms 10Pancreatic Neoplasms 9Endometrial Neoplasms 9Ovarian Neoplasms 8Cardiotoxicity 8Lung Neoplasms 7Esophageal Neoplasms 7Breast Diseases 7Uterine Cervical Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Prostatic Neoplasms 5Pathologic Complete Response 5Carcinoma, Ductal, Breast 5Urinary Bladder Neoplasms 4Sarcoma 4HER2-positive Early Breast Cancer 4HER2 Positive Breast Cancer 4Carcinoma, Renal Cell 4Carcinoma, Hepatocellular 4Thyroid Neoplasms 3

Interventions

spartalizumab 2durvalumab 2zanidatamab 1tremelimumab 1trastuzumab deruxtecan 1tislelizumab 1pembrolizumab 1obinutuzumab 1naptumomab estafenatox 1Trastuzumab 1Polymerase Chain Reaction 1Nivolumab 1Mass Spectrometry 1In Situ Hybridization, Fluorescence 1Immunohistochemistry 1Gemcitabine 1Capecitabine 1Albumin-Bound Paclitaxel 1Ado-Trastuzumab Emtansine 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma Of Esophagus × Trastuzumab × Breast × Clear all
NCT06324357 2026-05-26

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Boehringer Ingelheim

Phase 1/2 Recruiting
768 enrolled
BreastGastrointestinal

Adenocarcinoma Of Esophagus, Breast Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡